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ABSTRACT
Background: The modified painDETECT questionnaire (PDQ) is a self-reported questionnaire to discrimin-
ate between nociceptive and neuropathic-like pain in patients with knee/hip osteoarthritis (OA). This study
aims to assess the structural and construct validity of this questionnaire.
Methods: Confirmatory factor analysis and hypothesis-testing was used. For 168 patients, predefined
hypotheses were formulated on the correlation between the modified painDETECT and several other
questionnaires, and in a subsample of 46 with pain pressure thresholds (PPTs).
Results: Two principal components were confirmed. The pain pattern item did not load on any compo-
nent. Eighty per cent of the hypotheses on the correlation between modified PDQ and the questionnaires
were met, as were 50% concerning PPTs measurements.
Conclusions: This study is the first to assess structural and construct validity of the modified PDQ knee/
hip by using factor analysis and hypothesis-testing. This questionnaire seems to reflect neuropathic-like
pain symptoms experienced by hip/knee OA-patients with adequate validity. The item on pain pattern
might not reflect the construct. More than 75% of the predefined hypotheses regarding the modified
PDQ and the other questionnaires were met. Only 50% of the hypotheses on PPTs measurements were
met, probably due to heterogeneity and limited size of this subsample.
 IMPLICATIONS FOR REHABILITATION
 Pain in osteoarthritis (OA) is partly caused by modification of pain transmission in the peripheral and
central nervous system, leading to sensitisation. This process seems particularly significant in a sub-
group of OA patients.
 Sensitisation in OA is associated with more disability in daily life, lower quality of life and more wide-
spread pain, as well as poorer outcome of total joint surgery.
 Screening for sensitisation can help to identify the subgroup of patients who could benefit from
multidisciplinary treatment options focussing on desensitisation, cognitive- and behavioural therapy
and reducing chronification of widespread pain. Therefore, being particularly important in the field of
rehabilitation.
 The Dutch modified PainDETECT-questionnaire is very useful for rehabilitation professionals as it is
one of the first questionnaires specifically validated to assess neuropathic-like symptoms (indicating
sensitisation) in patients with knee or hip osteoarthritis.
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Introduction
Pain is the most disabling symptom of osteoarthritis (OA) and the
main reason for patients to seek medical consultation [1]. The
aetiology of OA pain is complex and multifactorial, involving both
intra- and extra-articular mechanisms [1–4]. A growing number of
studies suggest that modification of pain transmission in the per-
ipheral and central nervous system, leading to sensitisation, plays
a role in OA pain [4–12]. Sensitisation seems to be associated with
neuropathic pain-like symptoms. Sensitisation in OA is associated
with more disability in daily life, lower quality of life and more
widespread pain, as well as poorer outcome of total joint surgery
[13–18]. Assessment of these symptoms can help to identify
patients who could benefit from multidisciplinary treatment
options focussing on desensitisation, cognitive- and behavioural
therapy and reducing chronification of widespread pain [10].
In hip OA, up to 19% of the patients and in knee OA 19–37%
of the patients experience possible or likely neuropathic pain
[3,19–23]. Besides clinical assessment by specialised pain physi-
cians and elaborate protocols for physical examination for neuro-
pathic symptoms [quantitative sensory testing, (QST)], several
questionnaires are available to distinguish neuropathic pain symp-
toms from nociceptive pain symptoms. These questionnaires are
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applicable in the ambulatory setting, are easy to use, and do not
require specialised examiners. Most of these questionnaires con-
tain similar neuropathic pain descriptors, but because they have
been developed in different populations of neuropathic pain
patients, some differences exist between them [24–28].
When these questionnaires are applied to specific populations,
such as OA patients, validity of the tool needs to be re-evaluated
[28,29]. The painDETECT questionnaire (PDQ) is a self-reported ques-
tionnaire developed to discriminate between nociceptive and pos-
sible or likely neuropathic pain in patients with chronic low back
pain [30]. Hochman et al. modified the PDQ to fit knee OA patients
[19]. Recently this modified PDQ (mPDQ) was translated into Dutch
and adjusted to also fit hip OA patients, resulting in the mPDQ-NL
hip and knee [31]. The aim of this study was to assess the validity of
the mPDQ-NL in patients with hip or knee OA.
Methods
Validity was assessed including structural validity and construct
validity using elaborate hypothesis testing. For hypothesis-testing,
the mPDQ-NL was compared to several other self-reported ques-
tionnaires on both similar constructs (convergent validity) and dis-
similar constructs (divergent validity). Questionnaires used for this
purpose were the Self-reported Leeds Assessment of Neuropathic
Symptoms and Signs (S-LANSS), subscales of the Knee and Hip
disability and Osteoarthritis Outcome Score (KOOS/HOOS), Visual
Analogue Scale for pain (VAS pain) and subscales of the RAND-36
health survey (RAND-36).
In OA patients, the most reported somatosensory abnormality
from among the QST parameters is a reduced pain pressure
threshold (PPT) [7,32]. This could be considered a more objective
indication of sensitisation in OA compared to subjective self-report
questionnaires so additionally convergent validity was assessed
with blunt PPTs. The study was approved by the Medical Ethics
Committee of University Medical Center Groningen (number
METc2014/087). The procedures followed were in accordance with
the ethical standards of the responsible committee on human
experimentation and with the Helsinki Declaration of 1975, as
revised in 2000.
Participants and procedure
Hip or knee OA patients who were receiving conservative treat-
ment or were on the waiting list for total hip or knee arthroplasty
(THA/TKA) were eligible to participate in this study. These patients
were recruited from the outpatient clinics of the departments of
orthopaedic surgery of three hospitals situated in the northern
part of the Netherlands: University Medical Center Groningen,
Martini Hospital and Medical Center Leeuwarden. Exclusion criteria
were age below 18 years, neurological comorbidities, cognitive or
severe psychiatric disorders, and inadequate understanding of
written Dutch. A sample of 220 patients was approached and data
were collected between April 2014 and February 2015.
Eligible patients received an information letter and a set of
questionnaires by mail containing a questionnaire on demograph-
ics and comorbidities, mPDQ-NL, S-LANSS, KOOS/HOOS, VAS pain,
and RAND-36. Patients were asked to complete the questionnaires
and the information letter explained that returning a set of com-
pleted questionnaires was considered as informed consent to par-
ticipate in the study. If patients suffered from OA in more than
one joint they were asked to regard the hip or knee which was
most symptomatic when filling in the questionnaires. After two
weeks, a reminder was sent to non-responders. If questionnaires
had missing data, several attempts were done to complete the
items by telephone. A convenience sample of 46 patients was vis-
ited at home to perform measurements of PPTs. To constitute this
subgroup, patients were selected based on the shortest travelling
distance to the participating hospitals. Patients were asked by
telephone for consent to visit them and to measure their PPTs.
Questionnaires and measurements
Modified PDQ-NL
The mPDQ-NL is a self-administered questionnaire consisting of 12
items on neuropathic pain symptoms in the left or right knee or
hip during the past week. The first item concerns the presence of
pain radiation using a body map. The second item concerns pain
patterns, where patients have to choose between four figures rep-
resenting distinctly described pain patterns. The following seven
items concern pain quality on a 0–5 Likert scale, 0 representing
“never” and 5 representing “very strongly”. These items concern
burning sensation, tingling or prickling sensation, pain at light
touch, sudden pain attacks, pain at cold or warm stimulus, numb-
ness and pain at light pressure, respectively. The final three items
concern pain intensity on a 0–10 numeric rating scale (NRS),
where 0 represents “no pain” and 10 represents “excruciating
pain”. These final three items, respectively concern “pain at this
moment”, “worst pain in the past week” and “average pain in the
past week”. The total score ranges from 1 to 38 points. The final
three items on pain intensity are not included in the score.
Analogously to the original PDQ, a score of 12 indicates a noci-
ceptive pain profile, a score of 13–18 a possible neuropathic pain
profile, and a score 19 a likely neuropathic pain profile [30]. The
mPDQ-NL is considered to be a reliable self-report instrument in
patients with hip and knee OA, with a good internal consistency
(Cronbach’s alpha 0.77 for total score), and good repeatability
with a standard error of measurement of 2.6 points and an
intraclass correlation coefficient (ICC) of 0.90 [31].
Self-reported leeds assessment of neuropathic symptoms and
signs
The S-LANSS is a self-reported questionnaire to identify pain of
predominantly neuropathic origin in patients with chronic pain
from any cause [33,34]. The S-LANSS consists of seven items and
uses a weighed binary scoring system. The first five items concern
neuropathic pain symptoms. The last two items concern clinical
signs: patients are asked to gently rub and press the painful area
and compare it with a non-painful area. The total score ranges
from 0 to 24 points. A score of 12 points suggests pain of pre-
dominantly neuropathic origin. In addition, the S-LANSS contains
a body map for identifying pain sites and a 0–10 NRS for pain
over the last week. These last two items do not contribute to the
total score. The S-LANSS has proven to be a valid and reliable
self-report instrument for identifying neuropathic pain with a
discriminant validity between 73 and 75% compared to expert
clinical examination, and a good internal consistency with a
Cronbach’s alpha of 0.76. However, it has not been specifically
validated for hip or knee OA patients [25,27,28,34]. The Dutch ver-
sion of the S-LANSS used in the present study was translated and
cross-culturally adapted according to international guidelines [35].
Knee and hip disability and osteoarthritis outcome score
The HOOS, and KOOS are self-administered, disease-specific ques-
tionnaires designed to assess patients’ opinion about their knee
or hip symptoms and associated problems. Both scores consist of
five subscales. For this study the subscales for pain, other symp-
toms, and activities of daily living (ADL) were used. Answers are
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given on a 0–4 Likert scale. For each subscale, a normalised 0–100
score is calculated. These 0–100 scores were transformed so that
0 represents no symptoms and 100 represents extreme symptoms.
The HOOS and KOOS are considered reliable and valid instruments
in patients with hip and knee OA with good internal consistency
for each subscale (Cronbach’s alpha above 0.70 each), good test-
retest reliability with an ICC between 0.75 and 0.97 for the sub-
scales of the HOOS and an ICC above 0.70 for all subscales of the
KOOS, and an adequate construct validity in which 75% of the
predefined hypotheses were confirmed for the HOOS and more
than 60% for the KOOS [36,37].
VAS pain
VAS are widely used to measure pain. Patients place a marking on
a 100-mm horizontal line that represents their pain. The left end-
ing of the line represents “no pain at all” and the right ending
“worst pain imaginable”. The distance between the marking and
the left ending of the line is measured in whole millimetres and
represents the pain score. Patients were asked to record the aver-
age pain at rest during the last week in their hip or knee. VAS
have been reported as valid and reliable measures for the inten-
sity of pain with a between session reliability of r¼ 0.97, and a
good discriminative validity [38].
RAND-36
The Dutch RAND-36 Health Survey (RAND-36) is a widely used
self-administered, generic health status questionnaire that assesses
quality of life and well-being [39]. It contains 36 questions and
standardised response choices. These questions are divided into
eight different subscales. For this study, the subscales for bodily
pain and physical functioning were used. All scores are converted
to a 0-to-100 scale, with a higher score indicating higher levels of
functioning or well-being. The RAND-36 is considered a highly reli-
able instrument with good internal consistency for all subscales,
in which Cronbach’s alphas ranging between 0.71 and 0.91, and
satisfactory validity, with convergent validity correlations between
0.42 and 0.80 with corresponding questionnaires [40].
Pressure pain threshold
Blunt PPT measurements are part of QST. The procedure was
based on segments of the QST protocol of the original developers:
the German research network on neuropathic Pain [41]. PPTs were
measured using a pressure algometer (FDX25 Digital force gauge,
Wagner instruments, Greenwich CT) with a 1cm2 rubber tip. The
tip was placed perpendicular to the skin and pressure was exerted
with a slowly increasing force of 50 kgf/s (0.5 kg/s). Patients were
instructed to indicate the moment the pressure was experienced
as an unpleasant feeling and the algometer was removed immedi-
ately. The maximum force applied was noted. Before actual meas-
urements were performed patients were familiarised with the
procedure. At each site, the average of three measurements was
noted. In hip OA patients, PPT was measured 5 cm distally and
2 cm anteriorly of the greater trochanter on the side of the
affected hip. In knee OA patients, PPTs were measured at the
centre of the patella of the affected knee. In all patients PPT was
also obtained from a remote, unaffected location, namely 5 cm
proximally of the distal radio-ulnar joint contralaterally of the
affected hip or knee. Lowered PPTs at the affected joint area are
considered a reflection of peripheral sensitisation whereas lowered
PPTs at the remote site are considered a reflection of central sen-
sitisation [32]. All the measurements were performed by a single
assessor. PPTs have been used in numerous OA studies in
different body regions to assess sensitisation and altered
pain-processing, and have been proven reliable with ICCs ranging
between 0.77and 0.86 [2,14,17,18,23,32,42,43].
Statistical analysis
Statistical analyses were performed using IBM SPSS Statistics for
Windows (version 22.0, Armonk, NY: IBM Corp., NY). Patient char-
acteristics were reported using descriptive statistics consisting of
mean and standard deviation for variables with a normal distribu-
tion, and median and interquartile ranges for variables with a
non-normal distribution (duration of pain, S-LANSS, and PPT).
Structural validity
Structural validity concerns the degree to which the scores of a
measurement instrument are an adequate reflection of the dimen-
sionality of the construct to be measured and can be assessed
using (confirmatory) factor analysis [29]. Because the original PDQ
was developed for patients with chronic low back pain, it remains
to be investigated whether the items of the mPDQ adequately
reflect the neuropathic-like symptoms experienced by hip and
knee OA patients. Based on the two determinative components
described for the original PDQ, confirmatory factor analysis for
two principal components was performed according to Kaiser’s
criterion using varimax rotation [30]. If the loading of individual
items on one of the components is >0.5 this loading is consid-
ered adequate [29]. If items do not load on any of the compo-
nents they are considered as not being a good measurement of
the construct. Items should load substantially (>0.3) on only one
of the components and at least three items should contribute to
each component [29].
Construct validity
In order to determine construct validity predefined hypotheses
were formed based on similarities and differences between the
characteristics and constructs measured by the different measure-
ment instruments. In defining the hypotheses, previous studies
were also taken into account. According to the COSMIN criteria,
construct validity of a questionnaire is sufficient if 75% of prede-
fined hypotheses are met [29,44]. Pearson or Spearman correlation
coefficients were determined depending on normality of the dis-
tribution of the different scales. Correlation between mPDQ-NL
and S-LANSS was controlled for pain intensity. Correlation coeffi-
cients were interpreted according to criteria set by Domholdt
et al.: 0.00–0.25 represents little if any correlation; 0.26–0.49 weak
correlations; 0.50–0.69 moderate correlations; 0.70–0.89 strong cor-
relations; and 0.90–1.00 very strong correlations [45].
Tables 1 and 2 present the predefined hypotheses based on
the following: The constructs of the mPDQ and the S-LANSS are
considered the most similar, yet some important differences are
present between the two measurement instruments [24,27,28].
Examples of these differences are: (1) binary S-LANSS items ver-
sus Likert items in the mPDQ-NL, thereby producing quantitative
measurement; (2) a weighed scoring system in the S-LANSS versus
equal weighting of the mPDQ-NL items; (3) the S-LANSS contains
items regarding autonomic changes which are not characteristic
for OA, whereas the mPDQ-NL contains items regarding
evoked pain by heat or cold and numbness; (4) the mPDQ-NL is
joint-specific whereas the S-LANSS is not. Despite this, Hochman
et al. found a strong correlation of 0.73 between the mPDQ and
S-LANSS [19].
Correlations of the mPDQ-NL with pain scores of the VAS,
KOOS/HOOS and RAND-36 likely reflect the quantitative character
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of the mPDQ-NL; patients with more intense neuropathic-like pain
symptoms are expected to have a higher pain score. Likewise, the
ADL score of the KOOS/HOOS and the physical functioning score
of the RAND-36 are likely to be influenced by the severity of
neuropathic-like pain symptoms. The subscores of the KOOS/
HOOS are expected to show a higher correlation with the mPDQ-
NL than the RAND-36 subscores, as the latter concern general
instead of joint-specific symptoms. The KOOS/HOOS subscore for
other symptoms measures a divergent construct (e.g., stiffness,
effusion, crepitus), therefore, a weak correlation is expected with
the mPDQ-NL. No previous studies are available on the correlation
between mPDQ and the VAS pain or subscales of KOOS/HOOS
and RAND-36. However, some results are available for the correl-
ation between the PDQ (unmodified), VAS pain and subscales of
the RAND-36, reporting correlations between VAS pain and PDQ
of 0.39, and of 0.53 in hip and knee OA patients [20,46]. A correl-
ation of 0.30 between PDQ and the RAND-36 pain subscale was
previously described [42]. Based on previous studies, a weak cor-
relation of 0.30 was hypothesised between mPDQ-NL knee and
hip and the PPTs [42]. As the PPTs are most represented by the
specific mPDQ-NL item concerning pain at light pressure, the cor-
relation between this item and PPTs was expected to be higher
than between PPTs and mPDQ-NL total scores.
A minimal sample size of 100 participants was pursued as this
size is considered excellent for assessing measurement properties
of a questionnaire [47]. However, due to logistical challenges a
sample size of 50 participants was pursued for construct validation
of the mPDQ with PPT measurements.
Results
A total of 168 patients were included in the study (75 hip and 93
knee OA patients). Figure 1 shows the flow chart for inclusion.
PPT measurements were performed in 46 patients, consisting of
16 hip OA patients and 30 knee OA patients. Table 3 presents
patient characteristics and descriptive statistics of the collected
data.
Structural validity
Confirmatory factor analysis with two principal components
revealed two components with an Eigenvalue >1.0. The items
pain at light touch, light pressure and cold or warm stimulus load
adequately on the first component. The items radiation, burning
sensations and prickling sensations load adequately on the second
component. The items sudden pain attacks and numbness
substantially load on both factors. The item concerning pain pat-
tern does not load on any component. After removing the item
concerning pain pattern the distribution of the remaining item
loadings remained the same and the percentage of explained vari-
ance by both components increased from 48.7 to 53.9%.
Construct validity
Tables 1 and 2 present the correlation coefficients between
mPDQ-NL score and the different comparative measurement
instruments as well as accordance with the hypotheses. The
S-LANSS as well as PPTs in all body regions showed a non-normal
distribution, therefore, Spearman’s rho correlation coefficients
were calculated for these analyses whereas Pearson’s correlation
coefficients were calculated for the other instruments. In total,
80% of the predefined hypotheses concerning the self-reported
questionnaires were met. For PPT measurements, 50% of the pre-
defined hypotheses were met.
Table 1. Predefined hypotheses regarding other self-reported questionnaires.
Instrument compared Expected correlation Correlation coefficient Hypotheses confirmed?
S-LANSS 0.70–0.89 0.59 No
Higher than VAS Yes
VAS 0.50–0.69 0.51 Yes
KOOS/HOOS
Pain 0.50–0.69 0.64 Yes
Higher than RAND-36 bodily pain Yes
ADL 0.50–0.69 0.55 Yes
Higher than RAND-36 physical functioning Yes
Other symptoms 0.26–0.49 0.46 Yes
RAND-36
Bodily pain 0.26–0.49 0.25 No
Physical functioning 0.26–0.49 0.45 Yes
80%
ADL: Activities of daily living; Sport/Rec: function in sport and recreation; QOL: quality of life; Physic funct: physical functioning; Social funct:
social functioning; Role limit physic: role limitations due to physical health problems; Role limit emotional: role limitations due to emotional
health problems; VAS concerns the average pain in hip or knee at rest during last week. n¼ 168.
Figure 1. Flow chart showing inclusion procedure.
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Discussion
To our knowledge, this study is the first to assess the structural
validity of the mPDQ knee and hip by using factor analysis and to
assess construct validity using elaborate hypothesis-testing as pro-
posed by COSMIN guidelines [29,44]. A recent publication by
Mathieson et al. describes the poor overall methodological quality
of studies examining the measurement properties of neuropathic
screening questionnaires – they often lack factor analysis, do not
describe the percentage of missing values, and do not define clear
hypotheses a priori for construct validity [48]. Furthermore, few
validation studies have been conducted on screening question-
naires for neuropathic pain symptoms in the knee or hip OA
population. The percentage of cases lost to analysis due to miss-
ing items was<15%, therefore, selection bias is unlikely and the
results can be considered generalisable to the missing part of the
population [29]. The results of the present study, therefore, add
valuable data to this particular field of research.
Factor analysis confirmed two principal components for the
mPDQ. The distribution of items over these components was dif-
ferent when compared to literature on the unmodified PDQ
[30,49,50]. The item concerning pain pattern did not load on
either of the two components, suggesting that this item might
not reflect an aspect of the construct of neuropathic pain symp-
toms in hip or knee OA patients. After removing this item, the
percentage of explained variance by both components increased
from 48.7 to 53.9%. This is in line with previous data on Rasch
analysis of the unmodified PDQ by Moreton et al. who also found
a misfit of the pain pattern item in knee OA patients [42]. It might,
therefore, be advisable to remove this item from the mPDQ-NL
score. A possible explanation is the relatively mixed pain profile
experienced by knee and hip OA patients [23]. OA pain typically
fluctuates over time and gradually evolves from intermittent
weight-bearing to persistent chronic pain [2]. For some patients,
this pain is accompanied by neuropathic-like pain symptoms. This
is in contrast with studies on the unmodified PDQ in different
pain populations, where groups of patients with diagnosed neuro-
pathic pain conditions were compared to patients with typical
nociceptive pain conditions [30,49,50]. When interpreting the two
components of the mPDQ-NL, the items that only loaded on the
first component could be described as “evoked neuropathic
sensations”, the items that only loaded on the second component
as “spontaneous neuropathic sensations”. There were, however,
two Likert items that loaded substantially on both components.
For the Japanese unmodified PDQ, two similar principal compo-
nents were described for the seven Likert items, designated as
“spontaneous pain” and “evoked pain” [49]. It is not described
how the items were distributed among the two components,
therefore, it remains unclear whether the present results are really
in line with that study. Moreover, in the original PDQ and the
Spanish unmodified PDQ the seven Likert items all loaded on one
principal component [50]. It might thus be suggested that two
determinative components are present in the mPDQ-NL as well as
the unmodified PDQ, but results are inconsistent on this matter.
For construct validity, 80% of the predefined hypotheses con-
cerning other self-reported questionnaires were confirmed in a
substantial sample size of 168 patients. The confirmed hypotheses
validate the construct measured by the mPDQ-NL. Some hypothe-
ses were not confirmed though. The construct of the S-LANSS was
considered one of the most converging, and based on the previ-
ous study by Hochman et al. a strong correlation was expected,
yet only a moderate correlation was found. A possible explanation
is that Hochman et al. did not control for overall pain intensity,
contrary to our study [23]. This can be illustrated with the results
from the present study when comparing the correlation between
mPDQ-NL and S-LANSS (0.59), which was corrected for overall
pain intensity, with the correlation between the mPDQ-NL and
the pain subscore of the KOOS/HOOS (0.64), which was not
corrected.
Correlations between mPDQ-NL and the PPT measurements
did not meet our predefined hypotheses; only 50% of the prede-
fined hypotheses were confirmed in a considerably smaller sample
size of 46 patients. With regard to the mPDQ-NL item “pain at
light pressure”, only the PPTs at the hip joint showed a weak cor-
relation. Because both mPDQ-NL items and PPTs are associated
with sensitisation in OA, a weak correlation was expected. This
may be due to the relatively small and heterogeneous study
Table 3. Patient characteristics and descriptive statistics.
Self-reported
questionnaires (n¼ 168)
Subgroup PPT
sample (n¼ 46)
Age (years) 65 ± 10 (37–90) 65 ± 11 (41–90)
Gender
Female 105 (62.5%) 35 (76.1%)
Male 63 (37.5%) 11 (23.9%)
Body mass index (kg/m2) 28 ± 5 (18–45) 29 ± 6 (19–45)
Duration of pain (months)a 36 (18–72) 44 (24–96)
mPDQ-NL 12 ± 6 (0–36) 13 ± 5.5 (3–25)
S-LANSSa 8 (2–13)
VAS (mm) 33 ± 21 (0–85)
KOOS/HOOS
Pain 54 ± 19 (5–100)
ADL 59 ± 21 (3–100)
RAND-36
Bodily pain 53 ± 19 (0–90)
Physical function 54 ± 23 (0–100)
PPT (kgf)a (n¼ 46)
Arm 2.0 (1.5–2.0)
Hip area 3.1 (1.6–7.0)
Patella 3.7 (1.5–4.4)
m. tibialis anterior 2.2 (1.8–3.3)
Mean ± SD (min–max) for variables with normal distribution.
aMedian (IQ range) for variables with non-normal distribution. Gender is shown
as number of patients (%).
Table 2. Predefined Hypotheses regarding PPT measurements.
Instruments compared Expected correlation Correlation coefficient Hypotheses confirmed?
PPT
Arm 0.26 to 0.49 0.04 No
Hip area 0.26 to 0.49 0.05 No
Patella 0.26 to 0.49 0.09 No
PPT vs mPDQ-NL itema
Arm Higher than total mPDQ-NL correlation 0.08 Yes
Hip area Higher than total mPDQ-NL correlation 0.35 Yes
Patella Higher than total mPDQ-NL correlation 0.10 Yes
50%
PPT: Pressure pain threshold; mPDQ-NL: Dutch modified painDETECT Questionnaire. aPPTs correlated to mPDQ-NL item “pain at light
pressure”. n¼ 46.
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sample in terms of age, BMI and gender. In the literature, these
factors are identified to influence PPTs [41,51].
The study sample of the PPT subgroup however was too small
to correct for these factors, thereby hampering interpretability of
the present results. Assuming that the lack of correlation between
mPDQ-NL scores and PPTs found in the present study represents
the real relation between these two measurement instruments,
these results are an interesting contrast with our predefined
hypotheses. However, they support the theory of Wessel et al.,
who state that PPTs might be measuring different aspects of the
pain experience compared to patient-reported assessment of pain
experience. A patient’s own assessment of pain experience is con-
sidered to be influenced by subjective perception, which in turn is
influenced by factors other than the direct stimulation of nocicep-
tors. This could mean that direct comparison of subjective
patient-reported screening tools for neuropathic pain with more
objective measurement tools like PPT and QST in itself may
remain an interesting albeit ambivalent field for future
studies [52].
Assessment of neuropathic pain-like symptoms by means of
the mPDQ can be very useful to help identify the sensitised sub-
group of OA patients in order to optimally tailor treatment to the
individual patients’ needs [10,53]. These patients are more likely
to benefit from a multidisciplinary, cognitive, and behaviour-cen-
tred treatment program focussing on desensitisation, education,
and coping, as compared to somatic-pain centred surgical treat-
ment. Therefore, assessment tools like the mPDQ are especially
important to rehabilitation professionals working with OA
patients.
Conclusions
Overall it can be concluded that based on factor analysis and
elaborate hypotheses-testing, the mPDQ-NL seems to reflect
neuropathic-like pain symptoms experienced by hip and knee OA
patients with adequate validity. For construct validity, most of the
predefined hypotheses on correlation between the mPDQ-NL and
several other measurement instruments were met. Hypotheses on
PPT measurements were not met, probably due to heterogeneity
and limited sample size of this convenience subgroup. The
mPDQ-NL can thus be used to select patients with neuropathic-
like symptoms who may benefit from additional treatment options
in the multidisciplinary field of rehabilitation to improve their
physical and mental well-being. More research is needed into
effective interventions for this patient group.
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